Neurogenetics and Multi-omics of Neuroinflammatory Diseases in Multiplex Families to Improve Patients Health (NeuroDIP)
The goal of this observational study is to learn why some families have several members with multiple sclerosis (MS), neuromyelitis optica spectrum disorder (NMOSD), or MOG antibody-associated disease (MOGAD). These diseases happen when the immune system attacks the brain, optic nerves, or spinal cord. The study includes about 500 people from about 100 families: people with one of these diseases and their relatives who do not have it. The main question is: Do rare gene changes (variants) shared by family members explain why these diseases run in families? Researchers will compare the DNA of family members who have the disease with the DNA of relatives who do not. They will also look at how genes are switched on and off in blood cells. Participants will:
- Attend one visit of 2 to 3 hours at one of five French hospitals
- Answer questions about their health, treatments, and family history
- Give a 50 mL blood sample
연구 개요
상태
상태
정황
정황
개입 / 치료
개입 / 치료
상세 설명
Background: Large genetic studies have found many common gene variants that raise the risk of multiple sclerosis, but they explain only part of the inherited risk. They also explain familial forms poorly. Rare variants with a strong effect may be shared within a family and go unnoticed in studies of unrelated people. Families with several affected members are well suited to finding them. NeuroDIP combines genetic, epigenetic (DNA methylation), and gene expression data from these families and links them to clinical information.
Design: This is a cross-sectional, family-based study with a single visit and no follow-up. Comparing affected members with unaffected relatives from the same family helps limit the effect of ancestry and of factors that relatives share.
Visit: At the hospital, participants give written consent and have a short physical examination. Patients also have a disability assessment (EDSS). The investigator draws a family tree and records medical history, treatments, lifestyle, and any previous brain MRI report. A blood sample is then drawn. The study does not change usual medical care. Relatives are invited through the affected family member and are contacted by the investigating centre.
Samples and data: Samples and data carry a code, and names are kept only at the investigating centre. Samples are processed and stored in accredited biological resource centres. Research data are stored on secure servers in France and are not transferred outside the European Union. With participants' consent, coded data and samples may be used in future research on neuroinflammatory diseases, including deposit in the French MS registry (OFSEP).
Results: Participants do not receive individual research results. The exception is an incidental finding with health consequences, and participants must agree to be informed of such a finding before they take part. Participants can ask for the overall results and may be invited to an optional information meeting for families.
Funding: The study is funded by the Inserm Messidore 2024 call and by the ARSEP Foundation, and belongs to the NeuroDINet network on neuroinflammatory diseases.
연구 유형
연구 유형
등록 (추정된)
등록
단계
단계
- 해당 없음
연락처 및 위치
연구 연락처
연구 연락처
- 이름: David Axel LAPLAUD, MD PhD
- 전화번호: +33 240165176
- 이메일: david.laplaud@chu-nantes.fr
연구 연락처 백업
- 이름: Nicolas VINCE, PhD
- 전화번호: +33 253526229
- 이메일: nicolas.vince@univ-nantes.fr
연구 장소
-
-
-
Bron, 프랑스, 69500
- Hospice Civil de Lyon - Hospital Pierre Wertheimer
-
연락하다:
- Sandra VUKUSIC
- 전화번호: +33 04 72 68 13 13
- 이메일: sandra.vukusic@chu-lyon.fr
-
수석 연구원:
- Sandra Vukusic
-
Nantes, 프랑스, 44000
- University Hospital Laennec
-
수석 연구원:
- David-Axel LAPLAUD
-
연락하다:
- David-Axel LAPLAUD
- 전화번호: +33 02 40 16 52 00
- 이메일: david.laplaud@chu-nantes.fr
-
Nice, 프랑스, 06002
- University Hospital Pasteur 2
-
수석 연구원:
- Christine LEBRUN-FRENAY
-
연락하다:
- Christine LEBRUN-FRENAY
- 전화번호: +33 04 92 03 71 00
- 이메일: lebrun-frenay.c@chu-nice.fr
-
Paris, 프랑스, 75013
- Assistance Publique Hôpitaux de Paris- La Pitié Salpêtrière Hospital
-
연락하다:
- Céline a LOUAPRE
- 전화번호: +33 01 42 16 57 66
- 이메일: celine.louapre@aphp.fr
-
수석 연구원:
- Céline LOUAPRE
-
Rennes, 프랑스, 35000
- University Hospital Pontchaillou
-
수석 연구원:
- Laure MICHEL
-
연락하다:
- Laure MICHEL
- 전화번호: +33 02 99 28 42 66
- 이메일: laure.michel@chu-rennes.fr
-
-
참여기준
자격 기준
자격 기준
공부할 수 있는 나이
건강한 자원 봉사자를 받아들입니다
연구 대상 성별
설명
Inclusion Criteria:
-
Affected participants:
- Age 15 years and 3 months or older
- Multiple sclerosis (2024 McDonald criteria), neuromyelitis optica spectrum disorder with anti-AQP4 antibodies (2015 Wingerchuk criteria), or MOG antibody-associated disease (2023 international MOGAD panel criteria)
- Member of a multiplex family: at least two affected members sharing at least 12.5% of their genetic heritage
- Affiliated to a social security scheme or equivalent
- Written informed consent (for minors: assent of the minor and consent of the holders of parental authority)
-
Unaffected relatives:
- Age 18 years or older
- Sharing at least 25% of genetic heritage with one of the two affected family members
- No multiple sclerosis, NMOSD, MOGAD, or other known inflammatory disease of the central nervous system
- Affiliated to a social security scheme or equivalent
- Written informed consent
-
Transcriptomic sub-cohort (30 to 60 participants, about 10 families):
- Patients with no immunomodulatory or immunosuppressive treatment for at least 12 months, and their relatives
Exclusion Criteria:
- Refusal to participate before the inclusion visit
- Inability to understand the study information or to consent
- Person under guardianship, curatorship or legal protection
- Person deprived of liberty by judicial or administrative decision
- Pregnant or breastfeeding woman
- No kinship with at least one affected member of the included family
- Refusal to be informed of an incidental discovery of a pathogenic genetic variant
공부 계획
연구는 어떻게 설계됩니까?
디자인 세부사항
- 주 목적: 기초 과학
- 할당: 해당 없음
- 중재 모델: 단일 그룹 할당
- 마스킹: 없음(오픈 라벨)
팔의 수
무기와 개입
참가자 그룹 / 팔참가자 그룹 / 팔 |
개입 / 치료개입 / 치료 |
|---|---|
|
다른: Multiplex family members (patients and relatives)
Four participant categories (people with MS, NMOSD, MOGAD, and healthy) with their approximate numbers. |
One venous blood sample (50 mL) is drawn at a single visit. DNA is used for whole-genome sequencing. Cryopreserved peripheral blood mononuclear cells (PBMCs) are used for DNA methylation profiling and RNA sequencing. Serum is used to measure GFAP and NfL. |
연구는 무엇을 측정합니까?
주요 결과 측정
주요 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
Rare high-penetrance variants co-segregating with disease within multiplex families.
기간: 36 months from the first inclusion.
|
Proportion of rare (minor allele frequency < 1%), high-penetrance variants found in affected members and absent or significantly less frequent in unaffected relatives of the same family sharing at least 25% of their genetic heritage. Assessed by co-segregation and linkage analysis, family-based association tests and in silico prediction of variant impact. |
36 months from the first inclusion.
|
2차 결과 측정
2차 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
eQTL: genetic loci associated with gene expression in PBMC
기간: 36 months from the first inclusion.
|
Loci where genetic variants are associated with differences in gene expression in peripheral blood mononuclear cells (PBMC), from integrated whole genome sequencing and RNA sequencing data, in the untreated patient sub-group and their relatives. |
36 months from the first inclusion.
|
|
Disease-associated DNA methylation (CpG sites)
기간: 36 months from the first inclusion.
|
Number and type of CpG sites differentially methylated between patients and unaffected relatives, measured with EPIC arrays on PBMC DNA, in the untreated patient sub-group and their relatives. |
36 months from the first inclusion.
|
|
Transcriptomic signatures of PBMC subpopulations
기간: 36 months from the first inclusion.
|
Differentially expressed genes and perturbed pathways in immune cell subpopulations, from bulk and single-cell RNA sequencing of PBMC, comparing untreated patients (dedicated sub-cohort, n = 30 to 60) with their unaffected relatives. |
36 months from the first inclusion.
|
|
Multi-omic molecular signatures
기간: 36 months from the first inclusion.
|
Molecular signatures obtained by integrating genomic, DNA methylation and transcriptomic data (omicsNPC framework, multilevel modelling), used to model familial risk. |
36 months from the first inclusion.
|
|
Evaluation of the correlation with the disease phenotype
기간: 36 months from the first inclusion.
|
A potential correlation will be evaluated between genetic variants, DNA methylation, gene expression profiles and clinical data (age at onset , disease course, treatment response ) of patient. |
36 months from the first inclusion.
|
공동 작업자 및 조사자
스폰서
스폰서
협력자
협력자
수사관
수사관
- 수석 연구원: Nicolas VINCE, PhD, Nantes Université
간행물 및 유용한 링크
일반 간행물
- International Multiple Sclerosis Genetics Consortium. Multiple sclerosis genomic map implicates peripheral immune cells and microglia in susceptibility. Science. 2019 Sep 27;365(6460):eaav7188. doi: 10.1126/science.aav7188.
- Horjus J, van Mourik-Banda T, Heerings MAP, Hakobjan M, De Witte W, Heersema DJ, Jansen AJ, Strijbis EMM, de Jong BA, Slettenaar AEJ, Zeinstra EMPE, Hoogervorst ELJ, Franke B, Kruijer W, Jongen PJ, Visser LJ, Poelmans G. Whole Exome Sequencing in Multi-Incident Families Identifies Novel Candidate Genes for Multiple Sclerosis. Int J Mol Sci. 2022 Sep 28;23(19):11461. doi: 10.3390/ijms231911461.
- Wannaphut C, Ongphichetmetha T, Satiraphan P, Jitprapaikulsan J, Apiwattanakul M, Siritho S, Prayoonwiwat N, Savangned P, Rattanathamsakul N. Familial neuromyelitis optica spectrum disorders: Case series and systematic review. Mult Scler Relat Disord. 2023 May;73:104627. doi: 10.1016/j.msard.2023.104627. Epub 2023 Mar 21.
연구 기록 날짜
연구 주요 날짜
연구 시작 (추정된)
연구 시작
기본 완료 (추정된)
기본 완료
연구 완료 (추정된)
연구 완료
연구 등록 날짜
최초 제출
최초 제출
QC 기준을 충족하는 최초 제출
QC 기준을 충족하는 최초 제출
처음 게시됨 (실제)
처음 게시됨
연구 기록 업데이트
마지막 업데이트 게시됨 (실제)
마지막 업데이트 게시됨
QC 기준을 충족하는 마지막 업데이트 제출
QC 기준을 충족하는 마지막 업데이트 제출
마지막으로 확인됨
마지막으로 확인됨
추가 정보
이 연구와 관련된 용어
추가 관련 MeSH 약관
기타 연구 ID 번호
기타 연구 ID 번호
- C25-79
- 2026-A01125-46 (레지스트리 식별자: IDRCB)
약물 및 장치 정보, 연구 문서
미국 FDA 규제 의약품 연구
미국 FDA 규제 기기 제품 연구
이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .